反応式
CN1Cc2cnc(Cl)nc2O[C@H](c2ccccc2)C1.COc1cc(N)ccc1-n1cnc(C)c1>C1COCCO1.CC(=O)O.CC(=O)O.CC(C)(C)P(C(C)(C)C)C(C)(C)C.O=C([O-])[O-].[Cs+].[Cs+].[Pd]>COc1cc(Nc2ncc3c(n2)O[C@H](c2ccccc2)CN(C)C3)ccc1-n1cnc(C)c1参加物
7
反応物 2
生成物 1
試薬・触媒・溶媒 4
反応条件
- 温度
- 120 °C
実験手順
(R)-2-chloro-6-methyl-8-phenyl-5,6,7,8-tetrahydropyrimido[5,4-f][1,4]oxazepine (0.05 g, 0.18 mmol), 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)aniline (0.037 g, 0.18 mmol) (0.65), PALLADIUM(II) ACETATE (1.221 mg, 5.44 µmol), CESIUM CARBONATE (0.071 g, 0.22 mmol) and Tri-tert- butylphosphonium tetrafluoriborate (0.0043 g, 0.014 mmol, 6 mol%) in 1 ml of dioxane was degaset over argone and heated in MW 120°C 30 min. 002 - 4.8% of conversion mixture was heated more in MW 140°C 30 min. 003 - 15% of conversion mixture was heated more in MW 160°C 30 min. Experiment was not progressed.
出典と根拠
- ORDレコード
- ord-3d675e76027a44c193655dafbce49365
- 出典データセット
- 750 AstraZeneca ELN dataset
- 元リンク
- 出典を表示
関連ノート
読み込み中…